[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334877-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-334877-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","small-molecule-therapeutics-in-the-pipeline-targeting-for-triple-negative-breast-cancer-origin-challenges-opportunities-and-mechanisms-of-action","Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer - Origin, Challenges, Opportunities, and Mechanisms of Action","","Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, representing about 10–15% of breast cancers and showing aggressive invasion, faster growth, and higher risk of metastasis and recurrence. With chemotherapy still widely used, the review synthesizes histological and molecular TNBC subtypes, aberrant signaling pathways, and small-molecule inhibitors acting alone or combined with chemo, immunotherapy, or antibody–drug conjugates, including their mechanisms, challenges, and clinical-trial status.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/small-molecule-therapeutics-in-the-pipeline-targeting-for-triple-negative-breast-cancer-origin-challenges-opportunities-and-mechanisms-of-action/334877/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/small-molecule-therapeutics-in-the-pipeline-targeting-for-triple-negative-breast-cancer-origin-challenges-opportunities-and-mechanisms-of-action/334877.png","ImageObject",300,407,{"name":42,"@type":43},"Hazel","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What makes triple-negative breast cancer distinct from other breast cancer types?","Question",{"text":63,"@type":64},"TNBC cells lack estrogen receptors (ER), progesterone receptors (PR), and HER2. This receptor absence contributes to aggressive behavior and higher metastasis and recurrence risk.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which approaches are emphasized for TNBC treatment in the review?",{"text":68,"@type":64},"The review highlights chemotherapy and focuses on small-molecule therapeutics that target aberrantly expressed signaling pathways, used as single agents or combined with chemotherapeutics, immunotherapeutics, or antibody–drug conjugates.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is drug development for TNBC considered challenging?",{"text":72,"@type":64},"The review notes that the absence of key biomarkers makes targeted drug development difficult, while chemotherapy remains associated with chemoresistance and high toxicity to healthy cells.",{"name":74,"@type":61,"acceptedAnswer":75},"What signaling pathways and examples of small-molecule inhibitors are discussed?",{"text":76,"@type":64},"Pathways including VEGF, PARP, STAT3, MAPK, EGFR, PI3K, and SRC are discussed. Example inhibitors mentioned include buparlisib, everolimus, vandetanib, apatinib, olaparib, and salidroside.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},334877,1790486616,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":143,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":4},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Review  \nSmall Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action  \nNneoma James 1, Esther Owusu 1, Gildardo Rivera 2 and Debasish Bandyopadhyay 1,3, *  \nCitation: James, N.; Owusu, E.; Rivera, G.; Bandyopadhyay, D. Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action. Int. J. Mol. Sci. 2024, 25, 6285 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25116285  \nAcademic Editor: Nam Deuk Kim  \nReceived: 3 May 2024  \nRevised: 31 May 2024  \nAccepted: 3 June 2024  \nPublished: 6 June 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 School of Integrative Biological and Chemical Sciences, The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, TX 78539, USA; [nneoma.james01@utrgv.edu](nneoma.james01@utrgv.edu) (N.J.);  \n[esther.owusu01@utrgv.edu](esther.owusu01@utrgv.edu) (E.O.)  \n2 Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico; [giriveras@ipn.mx](giriveras@ipn.mx)  \n3 School of Earth Environment & Marine Sciences (SEEMS), The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, TX 78539, USA  \n* Correspondence: [debasish.bandyopadhyay@utrgv.edu](debasish.bandyopadhyay@utrgv.edu)  \nAbstract: Triple-negative breast cancer (TNBC) cells are devoid of estrogen receptors (ERs), progesterone receptor (PRs), and human epidermal growth factor receptor 2 (HER2), and it (TNBC) counts for about 10–15% of all breast cancers. TNBC is highly invasive, having a faster growth rate anda higher risk of metastasis and recurrence. Still, chemotherapy is one of the widely used options for treating TNBC. This study reviewed the histological and molecular characterization of TNBC subtypes, signaling pathways that are aberrantly expressed, and small molecules targeting these pathways, as either single agents or in combination with other therapeutic agents like chemotherapeutics, immunotherapeutics, and antibody–drug conjugates; their mechanisms of action, challenges, and future perspectives were also reviewed. A detailed analytical review was carried out using the literature collected from the SciFinder, PubMed, ScienceDirect, Google Scholar, ACS, Springer, and Wiley databases. Several small molecule inhibitors were found to be therapeutics for treating TNBC. The mechanism of action and the different signaling pathways through which the small molecules exert their effects were studied, including clinical trials, if reported. These small molecule inhibitors include buparlisib, everolimus, vandetanib, apatinib, olaparib, salidroside, etc. Some of the signaling pathways involved in TNBC, including the VEGF, PARP, STAT3, MAPK, EGFR, P13K, and SRC pathways, were discussed. Due to the absence of these biomarkers, drug development for treating TNBC is challenging, with chemotherapy being the main therapeutic agent. However, chemotherapy is associated with chemoresistance and a high toxicity to healthy cells as side effects. Hence, there is a continuous demand for small-molecule inhibitors that specifically target several signaling pathways that are abnormally expressed in TNBC. We attempted to include all the recent developments in this field. Any omission is truly unintentional.  \nKeywords: triple-negative breast cancer; breast cancer; estrogen receptor; human epidermal growth factor receptor 2; progesterone receptor; small molecules; chemotherapy; chemoresistance; immunotherapy; signaling pathway","cbCaikHQCYBe1ewO","https://ap.wps.com/l/cbCaikHQCYBe1ewO","pdf",1996229,25,"English","# Abstract\n# Keywords\n# 1. Introduction\n## Cancer burden and chemotherapy resistance\n## Breast cancer subtypes and biomarkers\n## Epidemiology by population and survival","[{\"question\":\"What makes triple-negative breast cancer distinct from other breast cancer types?\",\"answer\":\"TNBC cells lack estrogen receptors (ER), progesterone receptors (PR), and HER2. This receptor absence contributes to aggressive behavior and higher metastasis and recurrence risk.\"},{\"question\":\"Which approaches are emphasized for TNBC treatment in the review?\",\"answer\":\"The review highlights chemotherapy and focuses on small-molecule therapeutics that target aberrantly expressed signaling pathways, used as single agents or combined with chemotherapeutics, immunotherapeutics, or antibody–drug conjugates.\"},{\"question\":\"Why is drug development for TNBC considered challenging?\",\"answer\":\"The review notes that the absence of key biomarkers makes targeted drug development difficult, while chemotherapy remains associated with chemoresistance and high toxicity to healthy cells.\"},{\"question\":\"What signaling pathways and examples of small-molecule inhibitors are discussed?\",\"answer\":\"Pathways including VEGF, PARP, STAT3, MAPK, EGFR, PI3K, and SRC are discussed. Example inhibitors mentioned include buparlisib, everolimus, vandetanib, apatinib, olaparib, and salidroside.\"}]","Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer - Origin, Challenges, Opportunities, and Mechanisms of Action | PDF",1790008714,63]